by Richard Daverman, PhD
May 12, 2014 -- Aslan Pharma of Singapore signed a global license agreement to develop an anti-IL13 receptor monoclonal antibody from CSL Limited, an Australian biopharma. The molecule, CSL334, is currently in preclinical development for the treatment of asthma. Aslan will be responsible for developing CSL334 through clinical proof-of-concept, primarily in Asia. At that time, Aslan will identify a global partner for the Phase III trial and commercialization. CSL will receive a portion of the proceeds, though further financial details were not disclosed. More details....
Stock Symbol: (ASX: CSL)
Help employers find you! Check out all the jobs and post your resume.
